Abstract
Using proteomic approach in cerebrospinal fluid (CSF) we identified pigment epithelium-derived factor (PEDF) and Haptoglobin (Hp) as putative markers that could discriminate between AD and other dementias. ELISA assays were developed to measure the levels of PEDF and Hp in CSF from patients with AD (AD, n=27), non-AD (NAD, n=30) and in non-demented patients (ND, n=27). The combined assessment of PEDF, Hp and Tau levels, using Iterative Marginal Optimization, improved the differential diagnosis of AD, especially in patients with moderate to severe dementia (p<0.002). This pilot study highlights the probable different contribution of oxidative mechanisms in dementia.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / diagnosis*
-
Alzheimer Disease / metabolism
-
Alzheimer Disease / pathology
-
Amino Acid Sequence
-
Antibodies / metabolism
-
Biomarkers / cerebrospinal fluid*
-
Dementia, Vascular / diagnosis*
-
Dementia, Vascular / metabolism
-
Dementia, Vascular / pathology
-
Diagnosis, Differential
-
Enzyme-Linked Immunosorbent Assay
-
Eye Proteins / cerebrospinal fluid*
-
Female
-
Frontotemporal Dementia / diagnosis*
-
Frontotemporal Dementia / metabolism
-
Frontotemporal Dementia / pathology
-
Haptoglobins / cerebrospinal fluid*
-
Humans
-
Male
-
Middle Aged
-
Molecular Sequence Data
-
Nerve Growth Factors / cerebrospinal fluid*
-
Oxidation-Reduction
-
Pilot Projects
-
Proteomics
-
Serpins / cerebrospinal fluid*
-
Severity of Illness Index
-
tau Proteins / cerebrospinal fluid*
Substances
-
Antibodies
-
Biomarkers
-
Eye Proteins
-
Haptoglobins
-
Nerve Growth Factors
-
Serpins
-
pigment epithelium-derived factor
-
tau Proteins